FDA Ruling On Aussie Biotech Could Boost Congressman’s Investment
By Rachel Bluth
Innate Immunotherapeutics, whose largest shareholder is Buffalo-area Rep. Chris Collins, received FDA approval to begin U.S. trials of its drug for treating advanced multiple sclerosis.